Association of Endometriosis and Hormone Therapy with Risk of Hyperlipidemia.

Association of Endometriosis and Hormone Therapy with Risk of Hyperlipidemia. Am J Epidemiol. 2020 Aug 17;: Authors: Chang CY, Muo CH, Yeh YC, Lu CY, Lin WW, Chen PC Abstract We conducted a retrospective cohort study to investigate the risk of developing hyperlipidemia in women with endometriosis and hormone therapy using claims data from the universal health insurance of Taiwan. We selected 9,155 women aged 20-55 years with endometriosis diagnosed from 2000-2013 and 212,641 women without endometriosis with median follow-up of 7 years. Among patients with endometriosis, 86% were identified based on diagnosis codes with a claim of ultrasound, and 14% were defined by diagnostic laparoscopy or surgical treatments. In the Cox proportional hazards model, the adjusted hazard ratio (95% confidence interval) was 1.30 (1.19, 1.41) for all women, 1.04 (0.81, 1.32) among women <35 years old, 1.17 (1.03, 1.32) among those aged 35-44 years, and 1.34 (1.18, 1.52) among women aged 45-54 years. Hysterectomy and/or bilateral oophorectomy accounted for 46.9% in the association between endometriosis and hyperlipidemia, and hormone therapy accounted for 21.6%. Among women with endometriosis, the marginal structural model approach adjusting for time-varying hysterectomy/bilateral oophorectomy showed no association between hormone medications and risk of hyperlipidemia. We concluded that women with endometriosis are at an increased risk of hyperlipidem...
Source: Am J Epidemiol - Category: Epidemiology Authors: Tags: Am J Epidemiol Source Type: research